JPWO2019173602A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019173602A5 JPWO2019173602A5 JP2020546962A JP2020546962A JPWO2019173602A5 JP WO2019173602 A5 JPWO2019173602 A5 JP WO2019173602A5 JP 2020546962 A JP2020546962 A JP 2020546962A JP 2020546962 A JP2020546962 A JP 2020546962A JP WO2019173602 A5 JPWO2019173602 A5 JP WO2019173602A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- virus
- alkyl
- different
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023176993A JP2024009953A (ja) | 2018-03-07 | 2023-10-12 | 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862639725P | 2018-03-07 | 2018-03-07 | |
US62/639,725 | 2018-03-07 | ||
PCT/US2019/021168 WO2019173602A1 (fr) | 2018-03-07 | 2019-03-07 | Compositions thérapeutiques à base de nucléosides et de nucléotides contenant 4-halogène et utilisations associées |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023176993A Division JP2024009953A (ja) | 2018-03-07 | 2023-10-12 | 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021517132A JP2021517132A (ja) | 2021-07-15 |
JPWO2019173602A5 true JPWO2019173602A5 (fr) | 2022-03-14 |
JP7371931B2 JP7371931B2 (ja) | 2023-10-31 |
Family
ID=67846796
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020546962A Active JP7371931B2 (ja) | 2018-03-07 | 2019-03-07 | 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
JP2023176993A Pending JP2024009953A (ja) | 2018-03-07 | 2023-10-12 | 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023176993A Pending JP2024009953A (ja) | 2018-03-07 | 2023-10-12 | 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20210308168A1 (fr) |
EP (1) | EP3762372A4 (fr) |
JP (2) | JP7371931B2 (fr) |
KR (1) | KR20200140274A (fr) |
CN (1) | CN112074506A (fr) |
AU (1) | AU2019231725B2 (fr) |
BR (1) | BR112020018209A2 (fr) |
CA (1) | CA3093222A1 (fr) |
EA (1) | EA202092117A1 (fr) |
GB (2) | GB2611644B (fr) |
IL (1) | IL277160B1 (fr) |
PH (1) | PH12020551404A1 (fr) |
SG (1) | SG11202008527WA (fr) |
WO (1) | WO2019173602A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
AU2020418425A1 (en) * | 2019-10-08 | 2022-04-14 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
US20230167166A1 (en) * | 2020-04-24 | 2023-06-01 | Memorial Sloan Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
US20240025938A1 (en) * | 2020-08-27 | 2024-01-25 | Emory University | Novel forms of antiviral nucleosides |
AU2021401398A1 (en) * | 2020-12-18 | 2023-06-29 | Merck Sharp & Dohme Llc | Synthesis of antiviral nucleosides |
CN114644666A (zh) * | 2020-12-18 | 2022-06-21 | 上海特化医药科技有限公司 | 5’-核苷前药的制备方法及中间体 |
CN112608357B (zh) * | 2020-12-21 | 2022-12-09 | 杭州科巢生物科技有限公司 | 一种抗病毒药物Molnupiravir的制备方法 |
CN112778387A (zh) * | 2021-01-15 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种Molnupiravir晶型A及其制备方法 |
WO2022174179A1 (fr) * | 2021-02-15 | 2022-08-18 | Emory University | Compositions thérapeutiques à base de nucléosides et de nucléotides contenant du 4'-halogène et utilisations associées |
WO2022174194A1 (fr) * | 2021-02-15 | 2022-08-18 | Emory University | Compositions thérapeutiques à base de nucléosides et de nucléotides contenant du 4'-halogène et utilisations associées |
WO2022218274A1 (fr) * | 2021-04-15 | 2022-10-20 | 中国科学院上海药物研究所 | Analogue de nucléoside et son utilisation |
US11407779B1 (en) | 2021-04-23 | 2022-08-09 | Divi's Laboratories Ltd. | Process for the preparation of molnupiravir |
CN112979733B (zh) * | 2021-04-25 | 2021-09-10 | 南京颐媛生物医学研究院有限公司 | 抗乙肝病毒的化合物及其制备方法和应用 |
CN113278040B (zh) * | 2021-06-16 | 2022-07-05 | 苏州立新制药有限公司 | 5’-异丁酰基-n4-羟基胞苷的制备方法 |
WO2022262845A1 (fr) * | 2021-06-18 | 2022-12-22 | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. | Dérivés d'ester de n4-hydroxycytidine et leur utilisation |
WO2023012329A1 (fr) | 2021-08-06 | 2023-02-09 | Intervet International B.V. | Méthode de traitement de maladies virales vétérinaires |
CA3230382A1 (fr) | 2021-09-08 | 2023-03-16 | Aligos Therapeutics, Inc. | Molecules d'acide nucleique interferent court modifiees (sina) et leurs utilisations |
CN113880902A (zh) * | 2021-10-26 | 2022-01-04 | 江苏睿实生物科技有限公司 | 一种Molnupiravir药物中间体及其制备方法 |
US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
CN114478658A (zh) * | 2022-02-22 | 2022-05-13 | 苏州正济药业有限公司 | 一种莫那比拉韦的合成方法 |
CN116947947A (zh) * | 2022-04-20 | 2023-10-27 | 中国科学院上海药物研究所 | 抗病毒核苷类似物及其药物组合物和用途 |
CN117567310A (zh) * | 2023-11-28 | 2024-02-20 | 重庆智合生物医药有限公司 | 一种神经酰胺np1的合成方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4207363A1 (de) * | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung |
JPWO2004024185A1 (ja) * | 2002-09-11 | 2006-01-26 | 道男 石橋 | 医薬または化粧料 |
EP2068912A2 (fr) * | 2006-09-27 | 2009-06-17 | Coley Pharmaceutical Group, Inc. | Compositions de ligands tlr et d'antiviraux |
WO2009058800A2 (fr) * | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthèse de nucléosides |
US8962580B2 (en) * | 2008-09-23 | 2015-02-24 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
ES2636448T3 (es) | 2011-12-20 | 2017-10-05 | Riboscience Llc | Derivados de nucleósido 2',4'-difluoro-2'-metil sustituidos como inhibidores de la replicación del ARN del VHC |
AP3913A (en) * | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
EP2935304A1 (fr) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro-nucléosides pour le traitement du vhc |
KR102327888B1 (ko) | 2012-12-21 | 2021-11-17 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
US9187515B2 (en) * | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
WO2014186637A1 (fr) * | 2013-05-16 | 2014-11-20 | Riboscience Llc | Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués |
EP3013340B9 (fr) * | 2013-06-26 | 2023-10-04 | Janssen Pharmaceuticals, Inc. | Nucléosides, nucléotides substitués et leurs analogues |
WO2015051169A2 (fr) * | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Molécules de polynucléotides et leurs utilisations |
SG10201804835VA (en) * | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
AU2015280234B2 (en) * | 2014-06-24 | 2021-04-01 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
HUE051986T2 (hu) * | 2014-06-24 | 2021-04-28 | Janssen Biopharma Inc | Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra |
MA41441A (fr) * | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
WO2016134054A1 (fr) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Composés anti-viraux |
WO2016134056A1 (fr) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Composés anti-viraux |
BR112018002399A2 (pt) * | 2015-08-06 | 2018-09-25 | Chimerix, Inc. | nucleosídeos de pirrolopirimidina e análogos dos mesmos, úteis como agentes antivirais |
WO2017040892A1 (fr) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Composés anti-viraux |
WO2017040895A1 (fr) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Composés anti-viraux |
WO2017040896A1 (fr) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Composés anti-viraux |
US11963972B2 (en) * | 2016-03-23 | 2024-04-23 | Emory University | Antiviral agents and nucleoside analogs for treatment of Zika virus |
US20200179428A1 (en) * | 2016-06-20 | 2020-06-11 | Merck Sharp & Dohme Corp. | Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
-
2019
- 2019-03-07 JP JP2020546962A patent/JP7371931B2/ja active Active
- 2019-03-07 WO PCT/US2019/021168 patent/WO2019173602A1/fr unknown
- 2019-03-07 BR BR112020018209-5A patent/BR112020018209A2/pt unknown
- 2019-03-07 IL IL277160A patent/IL277160B1/en unknown
- 2019-03-07 GB GB2218405.5A patent/GB2611644B/en active Active
- 2019-03-07 EA EA202092117A patent/EA202092117A1/ru unknown
- 2019-03-07 AU AU2019231725A patent/AU2019231725B2/en active Active
- 2019-03-07 CA CA3093222A patent/CA3093222A1/fr active Pending
- 2019-03-07 EP EP19764729.0A patent/EP3762372A4/fr active Pending
- 2019-03-07 CN CN201980030574.4A patent/CN112074506A/zh active Pending
- 2019-03-07 SG SG11202008527WA patent/SG11202008527WA/en unknown
- 2019-03-07 GB GB2015827.5A patent/GB2589205B/en active Active
- 2019-03-07 KR KR1020207028655A patent/KR20200140274A/ko not_active Application Discontinuation
- 2019-03-07 US US16/979,108 patent/US20210308168A1/en not_active Abandoned
-
2020
- 2020-09-07 PH PH12020551404A patent/PH12020551404A1/en unknown
-
2023
- 2023-07-26 US US18/359,435 patent/US20240180948A1/en active Pending
- 2023-10-12 JP JP2023176993A patent/JP2024009953A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019173602A5 (fr) | ||
JP5108750B2 (ja) | Hdac阻害剤の医薬製剤 | |
US20110015273A1 (en) | Stable pharmaceutical aqueous compositions | |
GB2589205A (en) | 4'-halogen containing nucleotide and nucleotide therapeutic compositions and uses related thereto | |
ES2432666T3 (es) | Suspensión pediátrica estabilizada de carisbamato | |
JP2008522981A5 (fr) | ||
JP2010528051A (ja) | デング感染症の治療または予防のための抗ウイルス薬 | |
DE4218572A1 (de) | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E | |
BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
CH684054A5 (de) | Arzneimittel, welche als Wirkstoff Schwefel enthaltende Carbonsäuren enthalten. | |
EA034559B1 (ru) | Жидкая фармацевтическая композиция, содержащая пеметрексед | |
WO2001076570A2 (fr) | Utilisation de substances agissant en tant qu'inhibiteurs de la cascade de signaux raf/mek/erk pour produire un medicament contre les virus a adn et a arn | |
BR112012029212A2 (pt) | formulação de paracetamol injetável pronta para o uso estável | |
ES2318277T3 (es) | Composicion farmaceutica que compresnde acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico. | |
ES2272383T3 (es) | Uso de un agente que mejora la funcion astrocitica para el tratamiento de la enfermedad de parkison. | |
KR102605030B1 (ko) | 카바메이트 화합물을 포함하는 비경구용 액상 제제 | |
TW200812592A (en) | Use of strobilurins for the treatment of disorders of iron metabolism | |
US20190328663A1 (en) | Liposomes for the treatment of viral infections | |
JP6786504B2 (ja) | ウマにおける発熱の処置及び防止のための組成物及び方法 | |
ES2388253B1 (es) | Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia | |
US20060229356A1 (en) | Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions | |
EA202090172A1 (ru) | Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью | |
TWI316403B (en) | Glycyrrhizin containing pharmaceutical composition | |
US20090143313A1 (en) | Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds | |
BR112020012521A2 (pt) | agente terapêutico para glaucoma compreendendo agonista de fp e beta-bloqueador |